… of her department, aimed at developing a novel drug for Leber congenital amaurosis 10 (LCA10) patients, has … for our quest for treatments. Our lead program is for Leber congenital amaurosis (LCA), a rare genetic eye disease …
… – LCA10 and sepofarsen ProQR Expert Perspectives Series on Leber congenital amaurosis 10 and sepofarsen with Aniz Girach … lun 20/07/2020 - 18:00 ProQR Expert Perspectives Series on Leber congenital amaurosis 10 and sepofarsen with Aniz Girach …
ProQR to host a conference call to discuss the top-line results of the Phase 2/3 Illuminate clinical trial of investigational RNA therapy sepofarsen in CEP20-mediated LCA10.
… Medicines Agency (EMA) related to ProQR’s sepofarsen for Leber Congenital Amaurosis type 10 (LCA10). ProQR will focus … Medicines Agency (EMA) related to ProQR’s sepofarsen for Leber Congenital Amaurosis type 10 (LCA10). The information …
… fibrosis project that started it all. Then I worked on the Leber congenital amaurosis program, and then retinitis … testing sepofarsen, our investigational RNA therapy for Leber congenital amaurosis, in the organoids as well. It’s …
